Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sutantatug Envedotin · CRB-701

Antibody-drug conjugate · Cytotoxic, directed at nectin-4 · developed by Corbus Pharmaceuticals

Phase 3 Most advanced trial

CRBP Developer

1 Registered trials

What is Sutantatug Envedotin?

Sutantatug envedotin is an antibody-drug conjugate made of an IgG1 monoclonal antibody against nectin-4, linked through a cleavable linker to the cytotoxic agent monomethyl auristatin E (MMAE). After binding nectin-4 on tumor cells and internalization, MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is being studied in oropharyngeal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CRB-701
Drug type: Antibody-drug conjugate
Targets: nectin-4, tubulin (secondary target)
Mechanism: Cytotoxic, directed at nectin-4
Pathways: tubulin polymerization inhibition, G2/M phase arrest, apoptosis, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity
Therapy area: Oncology
Developer: Corbus Pharmaceuticals Inc. (CRBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: STG683M7KV

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07768189	Phase 3	Oropharyngeal Carcinoma (OPC)	Recruiting	CRBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Oropharyngeal Carcinoma (OPC)

Other drugs acting on NECTIN4

LY4052031 Phase 1 MK-3120 Phase 1/2

More from Corbus Pharmaceuticals

CRB-601 Phase 1/2 CRB-913 Phase 1 Extension Phase 2 JBT-101 Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CRBP page.

Follow CRBP, the company behind Sutantatug Envedotin

See CRBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z